Acurx Pharmaceuticals says it has received conditional acceptance from the U.S. Food and Drug Administration (FDA) for the proposed proprietary brand name “CIFBEZY” for its lead product candidate, ibezapolstat. The company also reports that the U.S. Patent and Trademark Office (USPTO) has granted a federal trademark allowance for the same name.
The approvals represent early milestones toward establishing the product’s commercial identity. PR Newswire describes the FDA conditional acceptance and trademark allowance as steps that will support the brand name’s use as ibezapolstat progresses. Investing.com similarly focuses on the FDA conditional acceptance, reporting the development without adding separate details on additional regulatory steps.
While both outlets align on the core events—FDA conditional acceptance and USPTO trademark allowance—their coverage differs in emphasis and scope, with PR Newswire also highlighting the trademark element as part of the same branding process.
